An observational study in Cirrhosis, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Centre Hospitalier Universitaire Dijon · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 172 studies in Fibrosis with a site in France — 34 open to participants now, 39 under way, 4 of them phase 3. Fibrosis · France.
Among the 172 studies in Fibrosis with a site in France, this one is the 27th largest by planned enrollment of the 54 observational ones that give a count, is one of 14 that started in 2025, is one of 54 observational ones, reaches primary completion later than 19 of the 38 other live ones, and was the 166th registered.
1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.
Browse Fibrosis studies →34 of the 172 studies in Fibrosis with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–70
Centre Hospitalier Universitaire de Besancon · Sites in France
E-Scopics · Sites in France
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 197 Fibrosis studies recruiting now, 112 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
172 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 27 · Phase 3 31 · Phase 4 4
First in 1994; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 157 across 386 observational studies indexed under Fibrosis.
Median enrollment 135 across the 117 interventional studies, 200 across the 54 observational. Of the 114 that completed or were terminated, 27 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 172 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire Dijon is the lead sponsor of 499 studies on the registry; 103 are open to participants now.
Centre Hospitalier Universitaire Dijon has 2 studies filed under Fibrosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Fibrosis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05874492Association Francaise pour la Recherche ThermaleEvaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer | 2026-12 |
| NCT06599892Hospices Civils de LyonCF Organization of Care in the Era of Highly Effective Modulator. | 2026-12-31 |
| NCT06327308Centre Hospitalier Universitaire de BesanconEvaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant. | 2027-03-11 |
| NCT06687265Assistance Publique - Hôpitaux de ParisEffects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension | 2027-03-30 |
| NCT06755632Assistance Publique - Hôpitaux de ParisScreening of Patients With Hepatic Fibrosis or Cirrhosis B and C | 2027-06-19 |
Add all 9 to your calendar (.ics) → With an account.
Among the 172 studies in Fibrosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fasting blood glucose is maintained by hepatic production of glucose from glycogenolysis or gluconeogenesis. In cirrhosis, glycogen storage capacity is reduced, with a consequent increase in gluconeogenesis to maintain blood glucose levels. Hypoglycaemia is particularly common during periods of prolonged nocturnal fasting. Cirrhosis can therefore be considered an 'accelerated fasting' disease. In a recent study, Honda et al. described 22% nocturnal hypoglycaemia in 105 patients analysed continuously. A previous study showed that the percentage of hypoglycaemia over the total duration of continuous blood glucose recording averaged 4%.
This gluconeogenesis could lead to a significant increase in muscle and fat catabolism, which would aggravate sarcopenia and lead to undernutrition. Undernutrition and sarcopenia are serious and severe in cirrhotic patients. Sarcopenia, present in around 45% to 67% of cirrhotic patients, is thought to lead to a significant increase in the morbidity and mortality of cirrhotic patients. Glycaemic disorders appear to play a major role in this sarcopenia. Shortening the duration of fasting, and therefore of proteolysis and lipolysis, by taking a snack in the evening, could improve nitrogen balance and glucose tolerance.
However, no study has clearly established the relationship between variations in continuous monitoring of interstitial glucose, particularly periods of nocturnal hypoglycaemia, and sarcopenia. New technologies in diabetology make it possible to obtain continuous monitoring of interstitial glucose. In addition, the use of muscle surface area at the level of the 3rd lumbar vertebra or the diameter of the psoas, obtained by scanner or MRI, combined with the use of a hand-held dynamometer to quantify muscle strength, make it easier to diagnose and assess the severity of sarcopenia and malnutrition.
The hypothesis of this work is based on the probable correlation between the time spent in hypoglycaemia (glycaemia \< 0.7 g/l) and the presence of sarcopenia responsible for undernutrition in cirrhotic patients.
If positive, the results of this descriptive pilot study could provide fundamental data for anticipating and better managing sarcopenia and glycaemic disorders. The results will enable a multi-centre randomised controlled intervention trial to be set up to optimise nutritional management of patients and thus effectively combat undernutrition in cirrhotic patients.
Cirrhotic subjects will be recruited from the hepato-gastroenterology departments of the centres taking part in this clinical study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with cirrhosis according to the 2021 EASL criteria
Other: fitting a blood glucose sensor · Other: food collection · Other: tests and questionnaires
automatic, continuous collection by the blood glucose sensor for 14 days
14-day dietary record in a notebook for the patient
fragility test, measurement of muscle strength using a hand-held dynamometer, animal enumeration test, self-questionnaire on the frequency of consumption of the main food groups
The number of nocturnal dysglycaemic events by the blood glucose sensor
Defined by an episode of hypoglycaemia (blood glucose \< 0.7 g/L), severe hypoglycaemia (blood glucose \< 0.55 g/L) or hyperglycaemia (blood glucose \> 1.8 g/L) lasting at least 15 consecutive minutes) of continuous recording of interstitial blood glucose (with Freestyle libre®). The nocturnal period is defined as the period between 11pm and 7am.
Time frame: For 14 days
Duration of nocturnal dysglycaemic events by the blood glucose sensor
Defined by an episode of hypoglycaemia (blood glucose \< 0.7 g/L), severe hypoglycaemia (blood glucose \< 0.55 g/L) or hyperglycaemia (blood glucose \> 1.8 g/L) lasting at least 15 consecutive minutes) of continuous recording of interstitial blood glucose (with Freestyle libre®). The nocturnal period is defined as the period between 11pm and 7am.
Time frame: For 14 days
The severity of nocturnal dysglycaemic events by the blood glucose sensor
Defined by an episode of hypoglycaemia (blood glucose \< 0.7 g/L), severe hypoglycaemia (blood glucose \< 0.55 g/L) or hyperglycaemia (blood glucose \> 1.8 g/L) lasting at least 15 consecutive minutes) of continuous recording of interstitial blood glucose (with Freestyle libre®). The nocturnal period is defined as the period between 11pm and 7am.
Time frame: For 14 days
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Oct 2027, 25 months after the start.
Of 177 non-industry observational studies under Fibrosis, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 105. This study's planned 25 months is below that.
Counting every sponsor, half of 186 studies reached it within 49 months; a quarter within 22 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire Dijon →